We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-20.59%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$178M
AUM Growth
-$20.4M
Cap. Flow
+$23M
Cap. Flow %
12.97%
Top 10 Hldgs %
100%
Holding
11
New
4
Increased
–
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$12.2M
2
EPIX
ESSA Pharma
EPIX
+$7.61M
3
PVLA
Palvella Therapeutics
PVLA
+$6.93M
4
CBAY
Cymabay Therapeutics
CBAY
+$1.77M

Top Sells

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$2.42M
2
JUNO
Juno Therapeutics, Inc.
JUNO
+$1.99M
3
AKAO
Achaogen Inc
AKAO
+$1M

Sector Composition

Rank Sector Weight
1 Healthcare 68.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
$54.1M 30.46%
1,329,512
-45,488
-3% -$1.99M
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$40.6M 22.88%
2,138,872
– –
EGLT
3
DELISTED
Egalet Corporation
EGLT
$34.9M 19.63%
2,645,558
– –
KYNB
4
Kyntra Bio
KYNB
$28.5M
$19.1M 10.76%
34,887
-4,000
-10% -$2.42M
NBRV
5
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$10.9M 6.13%
+4,584
New +$12.2M
EPIX
6
DELISTED
ESSA Pharma
EPIX
$6.88M 3.88%
+54,545
New +$7.61M
PVLA
7
Palvella Therapeutics
PVLA
$1.98B
$4.55M 2.56%
+31,049
New +$6.93M
TARA icon
8
Protara Therapeutics
TARA
$226M
$3.48M 1.96%
6,250
– –
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.83M 1.03%
223,457
– –
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
$1.26M 0.71%
+650,000
New +$1.77M
AKAO
11
DELISTED
Achaogen Inc
AKAO
– –
-166,450
Closed -$1M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q3 2015 Portfolio in Review

As of Q3 2015, Omega Fund Management held 11 positions worth $178M, down 10% from $198M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Omega Fund Management deployed $23M of net new capital in Q3 2015, opening 4 new positions. Its largest new stake was Nabriva Therapeutics plc Ordinary Shares Ireland: 4,584 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 61% a quarter earlier.

On the sell side, the largest reduction was Kyntra Bio, an estimated $2.42M trimmed.

  • Omega Fund Management's largest Q3 2015 buy was Nabriva Therapeutics plc Ordinary Shares Ireland: 4,584 shares worth $10.9M.
  • Omega Fund Management's biggest Q3 2015 reduction was Kyntra Bio, cutting an estimated $2.42M.
  • Omega Fund Management fully exited Achaogen Inc in Q3 2015, selling an estimated $1M.
  • Omega Fund Management's ten largest holdings make up 100% of its $178M portfolio in Q3 2015.
  • Omega Fund Management opened 4 new positions and closed 1 in Q3 2015.
  • Omega Fund Management's portfolio value fell 10% quarter-over-quarter to $178M.

Based on Omega Fund Management's 13F filing for Q3 2015, filed 4 Nov 2015.